Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Clinical management of advanced gastric cancer: The role of new molecular drugs.
[esophageal carcinoma]
Gastric
cancer
is
the
fourth
most
common
malignant
neoplasm
and
the
second
leading
cause
of
death
for
cancer
in
Western
countries
with
more
than
2000
0
new
cases
yearly
diagnosed
in
the
United
States
.
Surgery
represents
the
main
approach
for
this
disease
but
,
notwithstanding
the
advances
in
surgical
techniques
,
we
observed
a
minimal
improvement
in
terms
of
overall
survival
with
a
significant
increasing
of
relapsing
disease
rates
.
Despite
the
development
of
new
drugs
has
significantly
improved
the
effectiveness
of
chemotherapy
,
the
prognosis
of
patients
with
unresectable
or
metastatic
gastric
adenocarcinoma
remains
poor
.
Recently
,
several
molecular
target
agents
have
been
investigated
;
in
particular
,
trastuzumab
represents
the
first
target
molecule
showing
improvements
in
overall
survival
in
human
epithelial
growth
factor
2
-
positive
gastric
cancer
patients
.
New
molecules
targeting
vascular
epithelial
growth
factor
,
mammalian
target
of
rapamycin
,
and
anti
hepatocyte
growth
factor
-c-
Met
pathway
are
also
under
investigation
,
with
interesting
results
.
Anyway
,
it
seems
necessary
to
select
more
accurately
the
population
to
treat
with
new
agents
by
the
identification
of
new
biomarkers
in
order
to
optimize
the
results
.
In
this
paper
we
review
the
actual
"
scenario
"
of
targeted
treatments
,
also
focusing
on
the
new
agents
in
development
for
gastric
cancer
and
gastro-
esophageal
carcinoma
,
discussing
their
efficacy
and
potential
applications
in
clinical
practice
.
Diseases
Validation
Diseases presenting
"first target molecule"
symptom
esophageal carcinoma
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom